Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12622001001785
Ethics application status
Approved
Date submitted
8/07/2022
Date registered
15/07/2022
Date last updated
15/07/2022
Date data sharing statement initially provided
15/07/2022
Type of registration
Retrospectively registered

Titles & IDs
Public title
Physical Activity and Lung cancer Screening (PALS): a feasibility randomised controlled trial of exercise and physical activity in lung cancer screening.
Scientific title
Physical Activity and Lung cancer Screening (PALS): a feasibility randomised controlled trial of exercise and physical activity in lung cancer screening.
Secondary ID [1] 307517 0
None
Universal Trial Number (UTN)
Trial acronym
Linked study record
This is a substudy of the International Lung Screen Trial NCT02871856.

Health condition
Health condition(s) or problem(s) studied:
lung cancer screening
 326947 0
Condition category
Condition code
Cancer 324135 324135 0 0
Lung - Non small cell
Cancer 324136 324136 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Home based exercise program (in addition to written material and usual care) individualised to the person (their ability and safety to perform the exercises). The program will be conducted remotely medical staff and physiotherapists trained in the intervention protocol. The program will run for 8 weeks and participants will be encouraged to exercise at home unsupervised. The program consists of weekly video-conferencing and/or telephone call support for up to 30 minutes (choice up to participant) for 8 weeks. The home program will consist of;
a. Initial education session about symptom assessment and self-management including overcoming barriers to exercise will be included as part of the first remote exercise program session via telehealth or telephone.
b. Resistance training: comprised of 5 simple functional resistance exercises using gravity or body weight. These will be individualised to the participants ability. There will be a mix of upper body and lower body exercises. Examples include squats, static wall squats, sit-to-stands, calf raises, stair climbing, wall push-ups, shoulder presses and bicep curls. The aim will be to complete each exercise 8-15 times (repetitions) in 2 – 3 sets, depending on the individual participant (this will be assessed during the first session). If the participant has access to exercise equipment at home, such as light hand-held weights (< 5 kg) or theraband, we can utilise this equipment in their program should they wish too.
c. Aerobic exercise: comprised of a moderate intensity walking program as defined by a modified Borg score of 3 to 4 for shortness of breath, or targeting a heart rate of 65 to 76% estimated maximum heart rate.
d. Weekly progress review and goal setting, aiming to meet the Australian guideline recommendation for 150 to 300 minutes of moderate intensity physical activity (or 75 to 150 minutes of vigorous intensity physical activity) in addition to at least 2 days of muscle strengthening activities. The total number and duration of unsupervised resistance training and aerobic sessions will be determined after discussion with the participant. Demonstration of exercises will be provided either at the time of the assessment via telehealth or via email with provision of written and pictorial demonstrations. Adherence will be monitored by participant self-reporting and attendance checklists.

The intervention will be conducted independent to lung cancer screening scans, however baseline assessments will be scheduled at the same time as screening scans if feasible to minimise inconvenience to participant.
Intervention code [1] 323980 0
Lifestyle
Intervention code [2] 323997 0
Prevention
Comparator / control treatment
1. Usual care: No intervention, Participant will continue with pre-existing medical, nursing and allied health care.
2. Written material: Australia’s physical activity and sedentary behavior guidelines by the Department of Health will be provided to participants in person at the time of their enrollment. Use of the written material will be assessed at the 9 week assessment.

Comparison arms will run independent to lung cancer screening scans, however baseline assessments will be scheduled at the same time as screening scans if feasible to minimise inconvenience to participant.
Control group
Active

Outcomes
Primary outcome [1] 331947 0
1. Feasibility, assessed by proportion of home-based exercise sessions completed and recorded during weekly review sessions, of an 8-week multi-modal exercise program targeted at improving health related quality of life and physical activity levels of participants of lung cancer screening.
Timepoint [1] 331947 0
At 9 weeks from enrollment, following intervention completion.
Primary outcome [2] 331968 0
2. Safety of an 8-week multi-modal exercise program targeted at improving health related quality of life and physical activity levels of participants of lung cancer screening. Safety will be assessed by the number of adverse events occurring during or within 60 minutes following the intervention. Serious adverse events are defined as any adverse event related to the study that resulted in death or is life threatening, requiring hospitalisation, causing disability or incapacity. Minor adverse events were those that are directly caused by exercise such as: a minor fall (not resulting in a serious adverse event), new or progressive pain, transient neurological deficits, transient altered mental status, palpitations or progressive fatigue. Adverse events will be recorded by participant self reporting in accordance with Common Terminology Criteria for Adverse Events (CTCAE5.0).
Timepoint [2] 331968 0
At each weekly review during the intervention and at 9 weeks from enrollment, following intervention completion.
Primary outcome [3] 332000 0
Feasibility, assessed by the proportion of participants enrolled in the study when offered, of an 8-week multi-modal exercise program targeted at improving health related quality of life and physical activity levels of participants of lung cancer screening.
Timepoint [3] 332000 0
At 9 weeks from enrollment, following intervention completion.
Secondary outcome [1] 411691 0
Physical activity levels assessed by International Physical Activity Questionnaire.
Timepoint [1] 411691 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [2] 411765 0
Exercise capacity measured by 6 minute walk distance.
Timepoint [2] 411765 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [3] 411766 0
Isometric hand grip muscle strength measured using a dynamometer.
Timepoint [3] 411766 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [4] 411767 0
Body composition (muscle mass, fat mass), assessed by "InBody 770" Body Composition Analyser.
Timepoint [4] 411767 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [5] 411768 0
Mental well being assessed using the Hospital Anxiety and Depression Scale
Timepoint [5] 411768 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [6] 411871 0
Overall health and wellbeing assessed via 36-Item Short Form Health Survey.
Timepoint [6] 411871 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [7] 411872 0
Health related quality of life assessed by EuroQol five dimensions questionnaire
Timepoint [7] 411872 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.
Secondary outcome [8] 411873 0
Physical activity levels assessed by step count using an electronic pedometer for a 10-day period
Timepoint [8] 411873 0
9 weeks post commencement of intervention and 6 months post commencement of intervention.

Eligibility
Key inclusion criteria
People already enrolled in the International Lung Screening Trial (ILST, NCT02871856. ) at the Royal Melbourne Hospital.

To be eligible for the program patients must be:
- Women or men age 55 to 80 years at the time of recruitment to the ILST.
- Current or former smokers. A former smoker is defined as one who has stopped smoking for one or more years.
- An estimated 6-year lung cancer risk of greater than or equal to 1.51% based on the PLCOm2012 risk prediction model or greater than or equal to 30 pack-years smoking history (pack-year is defined as number of pack of cigarettes smoked per day multiply by the number of years smoked. If a participant stopped smoking for 6 months or more and then restarted smoking again, the time will be subtracted from the total duration of smoking in 0.5 year increments)
- ECOG performance status 0 or 1

Capable of providing, informed consent for screening procedures (low dose spiral CT)
Minimum age
55 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Unable to ambulate 100m independently +/- aid
Unable to safety complete the home-based components of the intervention.
Co-morbidity or medical status preventing exercise, for example acute uncontrolled cardiovascular or respiratory issues
Have a diagnosis of lung cancer

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation via computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
4/05/2022
Date of last participant enrolment
Anticipated
30/11/2022
Actual
Date of last data collection
Anticipated
31/05/2023
Actual
Sample size
Target
75
Accrual to date
50
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 22778 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment postcode(s) [1] 38059 0
3050 - Parkville

Funding & Sponsors
Funding source category [1] 311798 0
Charities/Societies/Foundations
Name [1] 311798 0
Royal Melbourne Hospital Foundation
Country [1] 311798 0
Australia
Primary sponsor type
Individual
Name
Asha Bonney
Address
Respiratory and Sleep Department, Royal Melbourne Hospital
300 Grattan Street Parkville VIC 3050
Country
Australia
Secondary sponsor category [1] 313265 0
Individual
Name [1] 313265 0
Renee Manser
Address [1] 313265 0
Respiratory and Sleep Department, Royal Melbourne Hospital
300 Grattan Street Parkville VIC 3050
Country [1] 313265 0
Australia
Secondary sponsor category [2] 313267 0
Individual
Name [2] 313267 0
Catherine Granger
Address [2] 313267 0
Department of Physiotherapy,
Royal Melbourne Hospital
300 Grattan Street Parkville VIC 3050
Country [2] 313267 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 311241 0
The Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 311241 0
Ethics committee country [1] 311241 0
Australia
Date submitted for ethics approval [1] 311241 0
Approval date [1] 311241 0
19/07/2021
Ethics approval number [1] 311241 0
HREC/74684/MH-2021

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 120426 0
Dr Asha Bonney
Address 120426 0
Respiratory and Sleep Department, Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Country 120426 0
Australia
Phone 120426 0
+61 493427708
Fax 120426 0
Email 120426 0
Asha.Bonney@mh.org.au
Contact person for public queries
Name 120427 0
Asha Bonney
Address 120427 0
Respiratory and Sleep Department, Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Country 120427 0
Australia
Phone 120427 0
+61 493427708
Fax 120427 0
Email 120427 0
Asha.Bonney@mh.org.au
Contact person for scientific queries
Name 120428 0
Asha Bonney
Address 120428 0
Respiratory and Sleep Department, Royal Melbourne Hospital
300 Grattan Street
Parkville VIC 3050
Country 120428 0
Australia
Phone 120428 0
+61 493427708
Fax 120428 0
Email 120428 0
Asha.Bonney@mh.org.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified, raw, line-by-line data for each participant will be made available on a case-by-case basis at the discretion of the principal investigator.
When will data be available (start and end dates)?
Following completion of the study and publication of results with no end date determined.
Available to whom?
De-identified, raw, line-by-line data for each participant will be made available on a case-by-case basis at the discretion of the principal investigator.
Available for what types of analyses?
De-identified, raw, line-by-line data for each participant will be made available on a case-by-case basis at the discretion of the principal investigator.
How or where can data be obtained?
De-identified, raw, line-by-line data for each participant will be made available on a case-by-case basis at the discretion of the principal investigator (email: Asha.Bonney@mh.org.au).


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
16575Statistical analysis plan  Asha.Bonney@mh.org.au
16576Study protocol  Asha.Bonney@mh.org.au
16577Ethical approval  Asha.Bonney@mh.org.au
16578Informed consent form  Asha.Bonney@mh.org.au



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.